Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
'The Little Mermaid' got 16 million views on Disney+ so far after being released earlier this month.
McDonald's said it would eliminate self-serve soda machines by 2032.
Online prices just saw their biggest drop in three years, according to new data.
U.S. small business sentiment dropped in August, for the first time since April.
Bloomingdale's named Olivier Bron its new chief executive, replacing Tony Spring, who will become CEO of Macy's.
Apple's 'Wonderlust' event will kick off Tuesday to showcase its newest products, including the iPhone 15 while Google is facing a federal antitrust lawsuit. Meanwhile, TikTok is rolling out ecommerce on its app.
Apple's 'Wonderlust' event kicked off on Tuesday.
The federal antitrust trial against Google will begin Tuesday.
Disney and Charter Communications reached a deal to end the blackout of Disney-owned stations.
Stocks opened lower in Tuesday's session on concerns over higher oil prices and after Monday's earnings report from Oracle that showed revenue came in weaker than expected.
